Renal glycogen handling in diabetes: A narrative review of diabetic kidney disease pathogenesis
Abstract
Kidney disease is a major microvascular complication of diabetes, affecting approximately 40% of individuals with diabetes, and is a leading cause of end-stage renal disease. Besides the functional consequences of hyperglycemia; hemodynamic alterations are well understood. Activation of the sorbitol and hexosamine pathways, formation of advanced glycated products, and prevailing oxidative stress in the background of diabetic hyperglycemia are determinants of diabetic kidney disease (DKD) and its progression. The contribution of ectopic glycogen deposition remains unexplored. Glycogen metabolism in the kidneys is well regulated under physiological conditions, yet chronic hyperglycemia disrupts this balance across podocytes, tubular cells, and the glomerulus. Abnormal glycogen buildup has been observed in experimental diabetes models and human biopsy samples. GSK3β inactivation and mTORC1 upregulation emerge as central regulators. Metformin and SGLT2 inhibitors alter renal glycogen flow via AMPK-dependent pathways, a potential avenue for therapeutic exploration. The significance of observational studies needs to be further explored for the potential involvement of glycogen buildup in the pathogenesis of DKD. This narrative review aims to provide a comprehensive understanding of glycogen metabolism, examine the dysregulation of key enzymes and signaling pathways, collate available evidence from animal and clinical studies and propose hypothesis that glycogen accumulation may…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.